BUFFALO, NY- July 19, 2023 – A new editorial paper was published in Oncotarget’s Volume 14 on May 26, 2023, entitled, “Combined targeting of HEDGEHOG signaling and BRD4 as a novel therapeutic option against melanoma.”
2023
Hairdressers, barbers, beauticians learn to detect melanomas to save lives
Hairdressers, barbers and beauticians often find themselves wearing multiple hats, taking on the roles of marriage counsellors, financial consultants, and career advisors.
Dr Sullivan on the Reduction of ctDNA With Tebentafusp in Metastatic Uveal Melanoma
Ryan J. Sullivan, MD, associate professor of medicine, Harvard Medical School, associate director. the Melanoma Program, Massachusetts General Cancer, discusses the early reduction of circulating tumor DNA (ctDNA) in patients with metastatic uveal melanoma treated with tebentafusp-tebn (Kimmtrak) and shares how these reductions could correlate with longer overall survival (OS) in patients with a best response of stable disease.
European Medicines Agency recommends Opdivo for treatment of earlier melanoma stages
Opdivo (nivolumab) is a programmed cell death protein 1 (PD-1) inhibitor.